Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies (NCT07211178)
🩺 Plain-English Summary (8th-Grade Level)
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.
Who can join: Review the eligibility criteria below.
Location: Birmingham Hematology Associates — Birmingham, Alabama
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
- There are no interventions in this observational study. (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Birmingham Hematology Associates — Birmingham, Alabama
- PIH Health Whittier Hospital — Whittier, California
- Cleveland Clinic Florida — Weston, Florida
- Southern Illinois Hospital Services — Carbondale, Illinois
- Cancer Care Specialist of Illinois — O'Fallon, Illinois
- Goshen Center for Cancer Care — Goshen, Indiana
- Trinity Health — Ann Arbor, Michigan
- Oncology Hematology Associates — Springfield, Missouri
- Cancer Care Specialist of Reno — Reno, Nevada
- Summit Medical Group — Florham Park, New Jersey
- University of Cincinnati Medical Center — Cincinnati, Ohio
- Nashville General — Nashville, Tennessee
- Cancer Care Northwest — Spokane Valley, Washington
- Gunderson Health — La Crosse, Wisconsin
📞 Contact the Study Coordinator
Phone: (833) 514-4187
Email: gemini-breast@tempus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Cancer
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer — Anniston, Alabama
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer — Los Angeles, California
- Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery — Durham, North Carolina
- TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) — Palo Alto, California
- A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer — Chicago, Illinois
- ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer — Duarte, California
Explore by condition: All Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.